The study aims to investigate how different molecular subtypes of metastatic breast cancer respond to palliative radiotherapy.
Prospective analysis of clinical outcomes
Comparison of local control across molecular subtypes
Assessment of progression-free survival rates
Luminal subtypes show better local control post-radiotherapy compared to TNBC and HER2+ subtypes.
Luminal subtypes exhibit improved progression-free survival compared to other subtypes.
Abstract
Luminal subtypes have better local control and progression-free survival post-HPRT compared to TNBC and HER2+ subtypes, which can further be used to stratify radiotherapy fractionation schedules.